Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001072613-24-000899 0001906837 XXXXXXXX LIVE 3 Common Stock, $0.0001 par value 10/27/2025 false 0001885522 640979100 Neumora Therapeutics, Inc. 260 Arsenal Place Suite 1 Watertown MA 02472 Mark McDonnell (773) 380 6600 ARCH Venture Management, LLC 8755 W. Higgins Road, Suite 1025 Chicago IL 60631 0001402439 N ARCH Venture Fund VII, L.P. WC N DE 0 33847838 0 33847838 33847838 N 20.6 PN 0001617237 N ARCH Venture Fund VIII Overage, L.P. WC N DE 0 33847838 0 33847838 33847838 N 20.6 PN 0001757011 N ARCH Venture Fund X, L.P. WC N DE 0 33847838 0 33847838 33847838 N 20.6 PN 0001757017 N ARCH Venture Fund X Overage, L.P. WC N DE 0 33847838 0 33847838 33847838 N 20.6 PN 0001906837 N ARCH Venture Fund XII, L.P. WC N DE 0 33847838 0 33847838 33847838 N 20.6 PN 0001544444 N ARCH Venture Partners VII, L.P. AF N DE 0 33847838 0 33847838 33847838 N 20.6 PN 0001782583 N ARCH Venture Partners X, L.P. AF N DE 0 33847838 0 33847838 33847838 N 20.6 PN 0001768905 N ARCH Venture Partners X Overage, L.P. AF N DE 0 33847838 0 33847838 33847838 N 20.6 PN 0001979765 N ARCH Venture Partners XII, L.P. WC N DE 0 33847838 0 33847838 33847838 N 20.6 PN 0001544443 N ARCH Venture Partners VII, LLC AF N DE 0 33847838 0 33847838 33847838 N 20.6 OO 0001616165 N ARCH Venture Partners VIII, LLC AF N DE 0 33847838 0 33847838 33847838 N 20.6 OO 0001769012 N ARCH Venture Partners X, LLC AF N DE 0 33847838 0 33847838 33847838 N 20.6 OO 0001979548 N ARCH Venture Partners XII, LLC AF N DE 0 33847838 0 33847838 33847838 N 20.6 OO 0001219042 N Robert Nelsen AF N X1 0 33847838 0 33847838 33847838 N 20.6 IN 0001219039 N Keith Crandell AF N X1 0 33847838 0 33847838 33847838 N 20.6 IN 0001219043 N Clinton Bybee AF N X1 0 3708794 0 3708794 3708794 N 2.3 IN 0001569248 N Kristina Burow AF N X1 111129 33847838 111129 33847838 33958967 N 20.7 IN 0001229592 N Steven Gillis AF N X1 0 31526272 0 31526272 31526272 N 19.2 IN Common Stock, $0.0001 par value Neumora Therapeutics, Inc. 260 Arsenal Place Suite 1 Watertown MA 02472 This Amendment No. 3 (the "Amendment No. 3") amends the Schedule 13D filed on September 29, 2023 (as amended, the "Original 13D"), related to the Common Stock, $0.0001 par value per share (the "Common Stock"), of Neumora Therapeutics, Inc. (the "Issuer") having its principal executive office at 260 Arsenal Place, Suite 1, Watertown, Massachusetts, 02472. Item 3 of the Original 13D is hereby amended and supplemented as follows: On October 27, 2025, AVF XII purchased 1,915,700 shares of Common Stock at a purchase price of $2.61 per share. The working capital of AVF XII was the source of the funds for the purchases. No part of the purchase price paid by AVF XII was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the shares of Common Stock described above. The total amount paid by for securities purchased in the above-listed transactions is as follows: AVF XII: $ 4,999,981.50 Item 5 of the Original 13D is hereby amended and supplemented as follows: AVF VII is the record owner of 1,387,228 shares of Common Stock ("AVF VII Record Shares"). AVP VII, as the sole general partner of AVF VII, may be deemed to beneficially own the AVF VII Record Shares. AVP VII LLC, as the sole general partner of AVP VII, may be deemed to beneficially own the AVF VII Record Shares. AVF VIII Overage is the record owner of 2,321,566 shares of Common Stock ("AVF VIII Overage Record Shares"). AVP VIII LLC, as the sole general partner of AVF VIII Overage, may be deemed to beneficially own the AVF VIII Overage Record Shares. AVF X is the record owner of 12,205,379 shares of Common Stock ("AVF X Record Shares"). AVP X LP, as the sole general partner of AVF X LP, may be deemed to beneficially own the AVF X Record Shares. AVP X LLC, as the sole general partner of AVP X LP, may be deemed to beneficially own the AVF X Record Shares. AVF X Overage is the record holder of 11,886,758 shares of Common Stock ("AVF X Overage Record Shares"). AVP X Overage LP, as the sole general partner of AVF X Overage, may be deemed to beneficially own the AVF X Overage Record Shares. AVP X LLC, as the sole general partner of AVP X Overage LP, may be deemed to beneficially own the AVF X Overage Record Shares. AVF XII is the record holder of 6,046,907 shares of Common Stock ("AVF XII Record Shares"). AVP XII LP, as the sole general partner of AVF XII LP, may be deemed to beneficially own the AVF XII Record Shares. AVP XII LLC, as the sole general partner of AVP XII LP, may be deemed to beneficially own the AVF XII Overage Record Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and managing directors, each of the Managing Directors and direct and indirect general partners of AVF VII and AVF VIII Overage may be deemed to share the power to direct the disposition and vote of the AVF VII Record Shares and AVF VIII Overage Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and investment committee members, each of the Investment Committee Members and direct and indirect general partners of AVF X, AVF X Overage and AVF XII may be deemed to share the power to direct AVF X Record Shares and AVF XII Record Shares (collectively with AVF VII Record Shares and AVF VIII Overage Record Shares, the "Record Shares"). Burow and Gillis have a pecuniary interest in AVP VII, and Burow has a pecuniary interest in AVP VIII LP and AVP VIII Overage LP, and while they do not have voting or dispositive power over AVF VII Record Shares or AVF VIII Record Shares, these shares were included in the beneficial ownership reporting for each. Burow is also the owner of 47,717 shares of common stock of the Issuer and is the holder of vested options to purchase 60,831 shares of Common Stock and options to purchase 2,581 shares of Common Stock that will vest within 60 days of this Schedule 13D ("Burow Options"). Each Reporting Person disclaims beneficial ownership of the Record Shares except for the shares, if any, held of record by such Reporting Person. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage (other than for Burow) was calculated based on 163,964,887 shares of Common Stock outstanding, as reported by the Issuer to the Reporting Persons. For Burow, the Burow Options were included in the number of shares of Common Stock outstanding. Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets. (ii) shared power to vote or to direct the vote: See line 8 of cover sheets. (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets. (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets. Except as set forth above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days. No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, shares beneficially owned by any of the Reporting Persons. Not applicable. ARCH Venture Fund VII, L.P. ARCH Venture Partners VII, L.P. its General Partner 10/29/2025 ARCH Venture Partners VII, LLC its General Partner 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/29/2025 ARCH Venture Fund VIII Overage, L.P. ARCH Venture Partners VIII, LLC its General Partner 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/29/2025 ARCH Venture Fund X, L.P. ARCH Venture Partners X, L.P. its General Partner 10/29/2025 ARCH Venture Partners X, LLC its General Partner 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director 10/29/2025 ARCH Venture Fund X Overage, L.P. ARCH Venture Partners X Overage, L.P. its General Partner 10/29/2025 ARCH Venture Partners X, LLC its General Partner 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director 10/29/2025 ARCH Venture Fund XII, L.P. ARCH Venture Partners XII, L.P. its General Partner 10/29/2025 ARCH Venture Partners XII, LLC its General Partner 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/29/2025 ARCH Venture Partners VII, L.P. ARCH Venture Partners VII, LLC its General Partner 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/29/2025 ARCH Venture Partners X, L.P. ARCH Venture Partners X, LLC its General Partner 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director 10/29/2025 ARCH Venture Partners X Overage, L.P. ARCH Venture Partners X, LLC its General Partner 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director 10/29/2025 ARCH Venture Partners XII, L.P. ARCH Venture Partners XII, LLC its General Partner 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/29/2025 ARCH Venture Partners VII, LLC /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Clinton Bybee 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell 10/29/2025 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen 10/29/2025 ARCH Venture Partners VIII, LLC /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/29/2025 ARCH Venture Partners X, LLC /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director 10/29/2025 ARCH Venture Partners XII, LLC /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/29/2025 Robert Nelsen /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen 10/29/2025 Keith Crandell /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell 10/29/2025 Clinton Bybee /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Clinton Bybee 10/29/2025 Kristina Burow /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Kristina Burow 10/29/2025 Steven Gillis /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Steven Gillis 10/29/2025 *This Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.2 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.